CSL

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

News

FDA green lights CSL's once-monthly HAE drug Andembry

CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.

News

First self-amplifying mRNA vaccine reaches Europe

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU.

White House signs pricing deals with nine more pharmas

Astellas bets on Vir cancer drug, and other licensing deals

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL will slash headcount and hive off vaccine business

FDA green lights CSL's once-monthly HAE drug Andembry

First self-amplifying mRNA vaccine reaches Europe

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

CSL

Editor's Picks